tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus]
(Synonyms: H2N-Tyr-Leu-His-Val-Glu-Pro-Glu-Lys-Glu-Val-OH ) 目录号 : GP10028
P53 binding protein fragment
![tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] Chemical Structure](/media/struct/GP1/GP10028.png "tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] Chemical Structure")
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
P53 is a sequence-specific DNA-binding oligomeric protein that can activate transcription from promoters bearing p53-binding sites. Whereas the activation region of p53 has been identified within the amino terminus, the location of the specific DNA-binding domain has not been reported1.
Tumor protein p53 binding protein (53BP1) has been identified in a yeast two hybrid screen as a protein that interacts with the central DNA-binding domain of p532. Similar to breast cancer susceptibility gene 13, 4 (BRCA1; 53BP1 enhances p53-dependent transcription5. Interestingly, the COOH terminus of 53BP1 contains tandem BRCA1 COOH terminus (BRCT) motifs.
53BP1 becomes hyperphosphorylated and rapidly relocates to the sites of DNA strand breaks in response to ionizing radiation. 53BP1 foci formation is reduced in ATM-deficient cells and can be inhibited by wortmannin in ATM wild-type cells. Moreover, radiation-induced hyperphosphorylation of 53BP1 is absent in cells treated with wortmannin, as well as in ATM-deficient cells. 53BP1 participates in DNA damage-signaling pathways and is regulated by ATM after ǃ-radiation6.
References:
1.J.Bargonetti, J. J. Manfredi et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity wlien generated from wild-type but not from oncogenic mutant p53 protein, Genes Dev. 1993 7: 2565-2574
2.Iwabuchi, K., P.L. Bartel, B. Li, R. Marraccino, S. Fields (1994) Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA91:6098-6102
3.Ouchi, T., A.N. Monteiro, A. August, S.A. Aaronson, H. Hanafusa (1998) BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA95:2302-2306
4.Zhang, H., K. Somasundaram, Y. Peng, H. Tian, D. Bi, B.L. Weber, W.S. El-Deiry BRCA1 physically associates with p53 and stimulates its transcriptional activity Oncogene16199817131721
5.Iwabuchi, K., B. Li, H.F. Massa, B.J. Trask, T. Date, S. Fields(1998) Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem 273:26061-2606
6.Irene Rappold, Kuniyoshi Iwabuchi, Takayasu Date, and Junjie Chen Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage-Signaling Pathways. JCB vol. 153 no. 3 613-620
| Cas No. | SDF | ||
| 别名 | H2N-Tyr-Leu-His-Val-Glu-Pro-Glu-Lys-Glu-Val-OH | ||
| Canonical SMILES | OC(C=C1)=CC=C1CC(N)C(NC(CC(C)C)C(NC(CC2=CN=CN2)C(NC(C(C)C)C(NC(CCC(O)=O)C(N3CCCC3C(NC(CCC(O)=O)C(NC(CCCCN)C(NC(CCC(O)=O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C57H87N13O18 | 分子量 | 1242.38 |
| 溶解度 | ≥ 124.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8049 mL | 4.0245 mL | 8.0491 mL |
| 5 mM | 0.161 mL | 0.8049 mL | 1.6098 mL |
| 10 mM | 0.0805 mL | 0.4025 mL | 0.8049 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet